Evidence map›Paper›PMID 34061369›Full record

ArticleJournal of surgical oncology2021

Is there a difference in utilization of a perioperative treatment approach for gastric cancer between safety net hospitals and tertiary referral centers?

Michael K Turgeon, Rachel M Lee, Jessica M Keilson, Michelle R Ju, Matthew R Porembka, Rodrigo E Alterio, Joshua Kronenfeld, Jashodeep Datta, Neha Goel, Annie Wang and 6 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of surgical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 1 country.

Michael K TurgeonDivision of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.ORCID http://orcid.org/0000-0001-7197-9007
Rachel M LeeDivision of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.ORCID http://orcid.org/0000-0003-2704-839X
Jessica M KeilsonDivision of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
Michelle R JuDivision of Surgical Oncology, Department of Surgery, University of Texas Southwestern Medical School, Dallas, Texas, USA.
Matthew R PorembkaDivision of Surgical Oncology, Department of Surgery, University of Texas Southwestern Medical School, Dallas, Texas, USA.ORCID http://orcid.org/0000-0003-1596-0058
Rodrigo E AlterioDivision of Surgical Oncology, Department of Surgery, University of Texas Southwestern Medical School, Dallas, Texas, USA.
Joshua KronenfeldDivision of Surgical Oncology, Department of Surgery, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA.ORCID http://orcid.org/0000-0003-4540-3658
Jashodeep DattaDivision of Surgical Oncology, Department of Surgery, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA.
Neha GoelDivision of Surgical Oncology, Department of Surgery, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA.
Annie WangDivision of Surgical Oncology, Department of Surgery, NYU Langone Health, New York City, New York, USA.
Ann Y LeeDivision of Surgical Oncology, Department of Surgery, NYU Langone Health, New York City, New York, USA.ORCID http://orcid.org/0000-0002-8143-2635
Manuel FernandezDivision of Surgical Oncology, Department of Surgery, University of Illinois College of Medicine, Chicago, Illinois, USA.
Harry RichterDivision of Surgical Oncology, Department of Surgery, University of Illinois College of Medicine, Chicago, Illinois, USA.
Ajay V MakerDivision of Surgical Oncology, Department of Surgery, University of California San Francisco, San Francisco, California, USA.
Shishir K MaithelDivision of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
Maria C RussellDivision of Surgical Oncology, Department of Surgery, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.ORCID http://orcid.org/0000-0003-1584-6992
Emory University · USThe University of Texas Southwestern Medical Center · USUniversity of Miami · USNYU Langone Health · USUniversity of Illinois Urbana-Champaign · USUniversity of California, San Francisco · US

Funding

Implementing a Maternal health and PRegnancy Outcomes Vision for Everyone (IMPROVE)UL1TR002378 · NCATS · EMORY UNIVERSITY · PI Andres J Garcia, Elizabeth O. Ofili · 2017 to 2026
$92.1M
J: NRSA Training CoreTL1TR002382 · NCATS · EMORY UNIVERSITY · PI HENRY M BLUMBERG, Vasiliki Michopoulos · 2017 to 2026
$8.5M
UM Calabresi Clinical Oncology Research Career Development AwardK12CA226330 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Alan Pollack · 2018 to 2026
$5.1M
Research Training Program in Surgical OncologyT32CA211034 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI MERCHANT, NIPUN B. · 2016 to 2025
$2.7M
NCATS NIH HHS TL1 TR002382NCATS NIH HHS UL1 TR002378NCI NIH HHS K12 CA226330NCI NIH HHS T32 CA211034
6 · The paper itself

Abstract

BACKGROUND AND

objectivesPerioperative therapy is a favored treatment strategy for gastric cancer. We sought to assess utilization of this approach at safety net hospitals (SNH) and tertiary referral centers (TRC). MATERIALS AND

methodsPatients in the US Safety Net Collaborative (2012-2014) with resectable gastric cancer across five SNH and their sister TRC were included. Primary outcomes were receipt of neoadjuvant chemotherapy (NAC) and perioperative therapy.

resultsOf 284 patients, 36% and 64% received care at SNH and TRC. The distribution of Stage II/III resectable disease was similar across facilities. Receipt of NAC at SNH and TRC was similar (56% vs. 46%, p = 0.27). Compared with overall clinical stage, 38% and 36% were pathologically downstaged at SNH and TRC, respectively. Among patients who received NAC, those who also received adjuvant chemotherapy at SNH and TRC were similar (66% vs. 60%, p = 0.50). Asian race and higher clinical stage were associated with receipt of perioperative therapy (both p < 0.05) while treatment facility type was not.

conclusionsThere was no difference in utilization of a perioperative treatment strategy between facility types for patients with gastric cancer. Pathologic downstaging from NAC was similar across treatment facilities, suggesting similar quality and duration of therapy. Treatment at an SNH is not a barrier to receiving standard-of-care perioperative therapy for gastric cancer.

Indexed as

Perioperative CareQuality of Health CareAgedFemaleFollow-Up StudiesGastrectomyHumansMaleMiddle AgedNeoadjuvant TherapyPrognosisRetrospective StudiesSafety-net ProvidersStomach NeoplasmsTertiary Care Centersgastric cancerhealth disparitiesperioperative therapysafety net hospitals

Identifiers

PMID34061369
PMCPMC8394621
OpenAlexW3164313355

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.